New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
17:27 EDTACHNAchillion to host conference call
Conference call to provide an update on the company's hepatitis C (HCV) development programs and 4Q12 earnings results will be held on February 20 at 5 pm. Webcast Link
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
09:57 EDTACHNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 13, 2014
06:07 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Subscribe for More Information
October 10, 2014
05:59 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Stocks with implied volatility above IV index mean; Avon Products (AVP) 61, Achillion (ACHN) 200 according to iVolatility.
October 9, 2014
06:08 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Stocks with implied volatility above IV index mean; Avon Products (AVP) 60, Achillion (ACHN) 195 according to iVolatility.
October 8, 2014
16:26 EDTACHNOn The Fly: Closing Wrap
Subscribe for More Information
15:49 EDTACHNAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
October 7, 2014
10:56 EDTACHNOptions with increasing implied volatility
Subscribe for More Information
09:36 EDTACHNActive equity options trading on open
Subscribe for More Information
October 6, 2014
11:09 EDTACHNOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use